Yahoo
NasdaqCM - Nasdaq Real Time Price USD

Viridian Therapeutics, Inc. (VRDN)

24.09 +0.75 (+3.21%)
At close: 4:00:01 PM EDT
24.09 0.00 (0.00%)
After hours: 4:00:49 PM EDT
Trade VRDN on Coinbase
Chart Range Bar
Loading chart for VRDN
  • Previous Close 23.34
  • Open 23.29
  • Bid 23.61 x 100
  • Ask 29.74 x 200
  • Day's Range 23.19 - 24.11
  • 52 Week Range 13.18 - 34.29
  • Volume 2,704,037
  • Avg. Volume 1,774,515
  • Market Cap (intraday) 2.729B
  • Beta (5Y Monthly) 1.10
  • PE Ratio (TTM) --
  • EPS (TTM) -3.39
  • Earnings Date Nov 4, 2026
  • Forward Dividend & Yield -- (0.00%)
  • 1y Target Est 36.20
  • Zacks Rating Neutral

Viridian Therapeutics, Inc. engages in discovering, developing, and commercializing treatments for serious and rare diseases. It develops IGF-1R therapies to treat thyroid eye disease (TED), including Veligrotrug, a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered, and Elegrobart, a low-volume, infrequently dosed subcutaneous IGF-1R. The company also develops an anti-thyroid-stimulating hormone receptor (TSHR) candidate for the treatment of Graves' disease and TED. Its portfolio of engineered inhibitors of the neonatal Fc receptor (FcFn) includes VRDN-006, a highly selective Fc fragment, and VRDN-008, a half-life extended bispecific FcRn inhibitor comprising an GC fragment and an albumin-binding domain designed to prolong IGG suppression. The company was formerly known as Miragen Therapeutics, Inc. and changed its name to Viridian Therapeutics, Inc. in January 2021. Viridian Therapeutics, Inc. was incorporated in 2010 and is headquartered in Waltham, Massachusetts.

www.viridiantherapeutics.com

252

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Biotechnology

Industry

Performance Overview

Trailing total returns as of 10/27/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

VRDN
22.59%
S&P 500 (^GSPC)
12.81%

1-Year Return

VRDN
6.88%
S&P 500 (^GSPC)
12.33%

3-Year Return

VRDN
94.59%
S&P 500 (^GSPC)
87.56%

5-Year Return

VRDN
34.51%
S&P 500 (^GSPC)
69.66%

Earnings Trends

View More

Earnings Per Share

GAAP
Normalized
GAAP
Normalized

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q2 FY26
Revenue 284k
Earnings -127.12M
Profit Margin -44,760.21%

Q3

FY25

Q4

FY25

Q1

FY26

Q2

FY26

-100M
-50M
0
50M
-80000.0%
-60000.0%
-40000.0%
-20000.0%

Analyst Insights

View More

Analyst Price Targets

22.00
36.20 Average
24.09 Current
50.00 High

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell

Latest Rating

Date 9/22/2026
Analyst RBC Capital
Rating Action Maintains
Rating Outperform
Price Action Raises
Price Target 36 -> 38

Statistics

View More

Valuation Measures

Annual
As of 10/26/2026
  • Market Cap

    2.64B

  • Enterprise Value

    2.00B

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (current)

    --

  • Price/Sales (ttm)

    31.70

  • Price/Book (mrq)

    4.69

  • Enterprise Value/Revenue

    28.17

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    -30.16%

  • Return on Equity (ttm)

    -65.74%

  • Revenue (ttm)

    71.13M

  • Net Income Avi to Common (ttm)

    -334.03M

  • Diluted EPS (ttm)

    -3.39

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    981.53M

  • Total Debt/Equity (mrq)

    36.96%

  • Levered Free Cash Flow (ttm)

    -275.5M

Compare

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Company Insights

Fair Value

24.09 Current

Dividend Score

0 Low
Sector Avg.
100 High

Hiring Score

0 Low
Sector Avg.
100 High

Insider Sentiment Score

0 Low
Sector Avg.
100 High

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: